Search clinical trials for: JNS001

Total 242 results

Pinteon Therapeutics, Inc

Completed

Safety and Tolerability of PNT001 in Healthy Adults

Healthy

United States
Vesper Biotechnologies ApS

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VES001 in Healthy Participants (SORT-IN-1)

Dementia, Frontotemporal

Netherlands
Renovo

Completed

Safety and Efficacy of RN1001(Avotermin) in Healthy Male Subjects

Cicatrix

United Kingdom
Shanghai Junshi Bioscience Co., Ltd.

Terminated

Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Peking University

Recruiting

Trial of Surufatinib Combined With Toripalimab in the Treatment of Peritoneal Metastatic Carcinoma of Gastrointestinal or Primary Peritoneal Cancer

Primary Peritoneal Cancer | Refractory Metastatic Digestive System Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma (JUPITER06)

Advanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic Chemotherapy

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI

Non-small Cell Lung Cancer

China
Fudan University

Unknown

Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study

Thyroid Cancer

China
Maruho Co., Ltd.

Completed

Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle

Rosacea

United States, France, United Kingdom, Germany, Canada, Netherlands, New Zealand, Australia, Sweden
Maruho Co., Ltd.

Completed

Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle

Rosacea

United States, France, United Kingdom, Germany, Australia, Canada, New Zealand, Netherlands, Sweden
Fudan University

Recruiting

DV Combined With Toripalimab for Renal Preservation in Solitary Kidney or Renal Insufficiency or Bilateral Multiple UTUC

Renal Insufficiency | Solitary Kidney | Upper Urinary Tract Urothelial Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Clinical Study of JS007 in Patients With Advanced Solid Tumors

Patients With Advanced Solid Tumors

China
Shanghai Junshi Bioscience Co., Ltd.
Sponsor GmbH

Active, not recruiting

A Pharmacokinetic Study of JS002 in Healthy Subjects

Health Volunteer

China
Shanghai Ninth People's Hospital Affiliated to...
Fudan University; First Affiliated Hospital of Fujian Medical University; Tianjin... and other collaborators

Recruiting

Concurrent Immunotherapy With Postoperative Radiotherapy in Intermediate/High Risk HNSCC Patients Unfit for Cisplatin: The IMPORT Study (IMPORT) (IMPORT)

Head and Neck Squamous Cell Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Toripalimab for Patients With Advanced Solid Tumors

Melanoma | Urological Cancer

China
Peking University Cancer Hospital & Institute

Unknown

Phase II Study in the Treatment of Patients With Advanced Mucinous Melanoma (BJCH-MM-0624)

Advanced Mucosal Melanoma

China
Fudan University

Not yet recruiting

Newly Emerging Immunotherapy for Pancreatic Cancer Treatment (FD-IMPACT)

Pancreatic Cancer

China
Renovo

Completed

Juvista in Scar Revision Surgery of Disfiguring Scars (Revise)

Cicatrix

Spain, France, Hungary, Italy, United Kingdom, United States, Denmark, Germany, Latvia, Poland
Fujian Cancer Hospital
Zhejiang Cancer Hospital; Jiangxi Provincial Cancer Hospital

Not yet recruiting

Triprilimab(JS001) and Chemotherapy Combined With Local Treatment for Multiple Metastatic NPC

Nasopharyngeal Carcinoma

China
Shanghai East Hospital
Shanghai Juvensis Therapeutics Biotechnology Company Limited

Recruiting

Myocardial Telomere Recapping Study for Dilated Cardiomyopathy (MERCURY-DCM)

Heart Failure | Dilated Cardiomyopathy

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

To Evaluate the Efficacy and Safety of JS002 in HoFH Patients

Hyperlipemia

China
Peking University
RemeGen Co., Ltd.

Recruiting

JS001 in Combination With RC48-ADC in Treatment of HER2-Positive Advanced Malignant Solid Tumors

HER2-Positive Solid Tumors

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Clinical Study of JS201 in Patients With Advanced Malignant Tumors

Patients With Advanced Malignant Tumors

China
ENCell

Completed

Determine the Safety and Dose of EN001 in Patients With Charcot-Marie-Tooth Disease (CMT) Type 1A

Charcot-Marie-Tooth Disease, Type IA

Korea, Republic of
Shanghai Junshi Bioscience Co., Ltd.

Not yet recruiting

Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipidemia

Primary Hypercholesterolaemia and Mixed Dyslipidemia

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

The Safety and Efficacy of Multiple-dose of JS002 in Subject With Hyperlipidemia

Hyperlipemia

China
Beau Nakamoto
Neuraltus Pharmaceuticals, Inc.

Terminated

NP001, Alzheimer's Disease, and Blood Markers of Inflammation

Alzheimer Disease

United States
Pinteon Therapeutics, Inc
United States Department of Defense

Terminated

Safety and Tolerability of PNT001 in Patients With Acute Traumatic Brain Injury (TBI)

Traumatic Brain Injury

United States
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Active, not recruiting

Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma

China
RemeGen Co., Ltd.

Recruiting

A Study of RC118 Plus Toripalimab in Patients With Locally Advanced Unresectable or Metastatic Solid Tumors

Advanced Solid Tumor

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor

Advanced Tumors

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of JS401

Hyperlipidemia

China
Shanghai Vinnerna Biosciences Co., Ltd.
Sponsor GmbH

Recruiting

The Mass Balance Study of [14C]JT001

Healthy Subjects

China
Senesco Technologies, Inc.

Unknown

Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)

Multiple Myeloma | Plasma Cell Leukemia | Multiple Myeloma in Relapse | Mantle Cell Lymphoma in Relapse | Diffuse Large B Cell Lymphoma in Relapse | Other B Cell Lymphoma in Relapse

United States, South Africa
Neuraltus Pharmaceuticals, Inc.

Completed

A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

United States
Neuraltus Pharmaceuticals, Inc.

Completed

Single-Ascending-Dose Safety/Tolerability of NP001 in Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

United States
Shanghai Vinnerna Biosciences Co., Ltd.

Recruiting

A Real-World Study of JT001 for COVID-19

COVID-19

China
Wuxi No. 4 People's Hospital

Not yet recruiting

Safety Study of 89Zr-NY001 PET Imaging in Patients

Solid Tumor, Adult

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

The Efficacy and Safety of JS002 PFS and AI in Patients With Primary Hypercholesterolemia and Mixed Hyperlipidemia

Hyperlipemia

China
Neuraltus Pharmaceuticals, Inc.

Completed

Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation

Amyotrophic Lateral Sclerosis

United States, Canada
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Clinical Trial Evaluated the Safety and Tolerability, Pharmacokinetic and Pharmacodynamics Profile, and Immunogenicity of a Single Dose of JS010 Injection in Healthy Subjects

Migraine

China
Shanghai Vinnerna Biosciences Co., Ltd.
Sponsor GmbH

Completed

JT001 (VV116) for the Treatment of COVID-19

Mild to Moderate COVID-19

China
Capella Bioscience Ltd
Centessa Pharmaceuticals plc

Terminated

Study of Intravenously Administered Anti-LIGHT Monoclonal Antibody CBS001 in Healthy Volunteers

Chronic Inflammatory Disease

United Kingdom
Maruho Co., Ltd.
Leiden University Medical Center

Completed

Pharmacodynamics, Safety and Efficacy of Topical Omiganan in Patients With External Genital Warts

Condylomata Acuminata (External)

Netherlands
ENCell

Recruiting

Evaluate the Safety and Efficacy of EN001 in Patients With Charcot-Marie-Tooth Disease Type 1A

Charcot-Marie-Tooth Disease Type 1A

Korea, Republic of
Binhui Biopharmaceutical Co., Ltd.

Not yet recruiting

OH2 Administered by Intratumoral Injection

Solid Tumor
Shanghai JunTop Biosciences Co., LTD
Sponsor GmbH

Terminated

JT001 (VV116) for the Early Treatment of COVID-19

Mild to Moderate COVID-19

China, Hong Kong
Sun Yat-sen University

Active, not recruiting

Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients

Nasopharyngeal Carcinoma

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)

Non Small Cell Lung Cancer Recurrent
Maruho Co., Ltd.

Completed

Pharmacodynamics, Safety/Tolerability and Efficacy of Topical Omiganan in Patients With uVIN

Usual Type Vulval Intraepithelial Neoplasia (uVIN)

Netherlands

Search clinical trials for: JNS001

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Serbia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations